Commentary on “Liver function effects of SGLT2 inhibitor and GLP‐1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study)”

Ítems similars

• Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study
  per: Yoshimi Muta, et al.
  Publicat: (2024-03-01)
• Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication
  per: Kazuo Kobayashi, et al.
  Publicat: (2023-12-01)
• Concomitant treatment with insulin and sodium–glucose cotransporter 2 inhibitors was associated with the renal composite outcome in Japanese patients with type 2 diabetes and chronic kidney disease: A propensity score‐matched analysis
  per: Masao Toyoda, et al.
  Publicat: (2022-09-01)
• SGLT1 and SGLT2 inhibition, circulating metabolites, and cerebral small vessel disease: a mediation Mendelian Randomization study
  per: Yanchen Lv, et al.
  Publicat: (2024-05-01)
• The impacts of SGLT2 inhibitors on the mortality of patients with tuberculosis
  per: Chung-Shu Lee, et al.
  Publicat: (2025-05-01)